CDH1 and breast cancer: Enrichment of aberrant Hh signaling mechanisms in aggressive, metastatic and chemoresistant breast cancers types lead to low levels of E-cadherin and increased expression of FOXC2, SIP1, Snail, and Twist, vimentin, fibronectin and N-cadherin[14,24,38].